Switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF, Genvoya) single-tablet therapy was found to be non-inferior to remaining on an abacavir/lamivudine (ABC/3TC, Epzicom)-based regimen in a phase 3b study funded by Gilead Sciences, Inc., the manufacturer of E/C/F/TAF, that was published in AIDS.
All 274 participants were virally suppressed on an ABC/3TC-based regimen at baseline. They were randomized 2:1 to switch to E/C/F/TAF immediately (183 people) or after 24 weeks (91 people) for a total study period of 48 weeks. The current results are from week 24.
Virologic response was maintained by 93% in the new drug group and 98% in the prior regimen group. No study drug-related adverse events were reported in the ABC/3TC arm, but 18% of participants in the E/C/F/TAF arm experienced such events and 4% discontinued as a result. Participants on the single-tablet regimen reported higher treatment satisfaction (mean 23.7 on a 30-point scale) than those on the older regimen (mean 17.7). Eighteen participants discontinued before week 24 (15 in the immediate-switch arm and 3 in the delayed-switch arm).
Results show E/C/F/TAF to be efficacious and well tolerated with greater treatment satisfaction, study authors concluded.